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The vascular endothelium plays a fundamental role in the maintenance of tissue homeostasis, regulating local
blood flow and other physiological processes. Chemotherapeutic drugs and target therapies, including
antiangiogenic drugs targeting vascular endothelial growth factor (VEGF) or its receptors, not only efficiently act
against tumor growth, but may also induce endothelial dysfunction and cardiovascular toxicity. Continued research
efforts aim to better understand, prevent and mitigate these chemotherapy associated cardiovascular diseases.
Conventional chemotherapeutic agents, such as anthracyclines, platinum compounds, and taxanes, and newer
targeted agents, such as bevacizumab, trastuzumab, and tyrosine kinase inhibitors, have known risk of
cardiovascular toxicity, which can limit their effectiveness by promoting increased morbidity and/or mortality. This
review describes a) the activity of anticancer agents in inducing endothelial dysfunction, b) the metabolic pathways
and signalling cascades which may be targeted by protective agents able to maintain or restore endothelial cell
function, such as endothelial nitric oxide synthase/fibroblast growth factor-2 (eNOS-FGF-2) pathway, and c) the
drugs/strategies reported to improve endothelial function and to reduce the risks of cardiovascular diseases such as
angiotensin converting enzyme inhibitors (ACEi) and beta blockers, that are fundamental therapies in chronic heart
failure (HF), as well as non-standard HF treatments such ad nitric oxide donors and antioxidant strategies. There is
increasing interest in whether ACEi, beta-blockers, and/or statins might prevent and/or therapeutically control
cardiotoxic effects in cancer patients. Maintaining endothelial function during or following treatments with
chemotherapeutic agents, without affecting anti-tumor drug-effectiveness, is essential for preserving or recovering
cardiovascular homeostasis. In this respect, the early detection and immediate therapy of cardiovascular toxicity
appear crucial for substantial recovery of cardiac function in cancer patients.Background
Cardiac endothelial cells (ECs) play a fundamental role
in heart function. The myocardium is composed of
cardiomyocytes and non-myocytes, fibroblasts and ECs,
which work in concert for proper heart functioning [1].
Indeed, while cardiomyocytes generate the contractile
force, fibroblasts secrete components of extracellular
matrix and paracrine factors, and ECs line the coronary
vasculature and allow delivery, via the bloodstream, of
the free fatty acids and oxygen required to meet the
high metabolic demands of the contractile myocytes
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activates downstream intracellular signalling as the path-
ways extracellular related kinase1/2 (ERK1/2) and phos-
phatidylinositol 3-kinase (PI-3 K) involved in contractile
function and cardiomyocyte survival and proliferation [3].
A healthy endothelium is essential for the homeostasis
of the whole cardiovascular system. On the other hand,
endothelial dysfunction is associated with the pathophysi-
ology of various diseases including atherothrombosis, dia-
betes, sepsis, pulmonary hypertension, microangiopathies
associated with neurodegenerative diseases, liver steatosis
and cancer metastasis [4]. Mature ECs, endothelial pro-
genitor cells and circulating ECs participate to the physio-
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vessel remodelling and angiogenesis, coagulation and fi-
brinolysis (Fig. 1). Indeed, it has been proposed that endo-
thelial function can be regarded as a “barometer for
cardiovascular risk” [5, 6].
Cardiovascular toxicity by chemotherapeutic drugs
In general, chemotherapy is accompanied by systemic
endothelial dysfunction, increasing the cardiovascular
disease (CVD) risk and promoting vascular complica-
tions [7]. Cancer patients with concomitantly impaired
systemic endothelial function may be particularly sus-
ceptible to the detrimental effects of anticancer medica-
tions. Patients treated with cardiotoxic cancer therapies
manifest multiple risk factors such as hypertension,
obesity, dyslipidemia and metabolic syndrome, further
worsening vascular reserve and resulting in increased
risks of cardiotoxicity, which can limit cancer therapies
effectiveness by promoting increased morbidity and/or
mortality [8].
Conventional chemotherapy
Cancer therapy-induced endothelial cytotoxicity and car-
diotoxicity are due to a combination of “on-target” and
“off-target” effects. In particular, cancer therapies may
target signaling cascades that promote cancer cellFig. 1 Quiescent endothelial cells (ECs) participate to the physiological ma
vessel tone, permeability and intima thickness, coagulation and fibrinolysis,
peptides as BK and SP modulate the production/release of vasoactive mole
activate intracellular signalling pathways as MAPK and cGMP pathways, and
and proliferation. Endothelial loss-of-function/dysfunction following exposu
including VEGF/VEGFR inhibitors. Cancer therapies damage essential signali
protect endothelial cells, especially in response to stress. Endothelial dysfun
of vessel permeability, an increase of platelet adhesion and aggregation, and
vasoconstriction and reduced EC trofism and survival. Endothelial dysfunction
shown to improve endothelial function and to reduce the risk of cardiovascu
Among these, there are ACEi, ARBs, renin and β1 antagonist, NO donor drugs
factor; BK: bradykinin; SP: substance P; NO: nitric oxide; ET: endothelin; PGI2: p
cGMP: cyclic guanosine monophosphate; FGF2: fibroblast growth factor; VSMproliferation, but also protect ECs and cardiomyocytes,
especially in response to stress (Table 1). The develop-
ment of molecules/strategies capable of inducing robust
anti-tumor responses concurrent with minimal systemic
side effects is crucial for the improvement of chemother-
apy in oncology.
Mechanisms dependent on reactive oxygen-species
(ROS) were among the first to be linked to endothelial
toxicity of chemotherapeutics [9] (Fig. 1). Indeed, cardiac
and endothelial toxicity of anthracyclines was attributed
to redox activation of anthracyclines to semiquinone
intermediates, which generate superoxide radicals upon
reduction [10]. Both the superoxide anion and its dismu-
tation product - hydrogen peroxide - possess inherent
toxicity [11].
Anthracyclines are anticancer compounds that were ori-
ginally derived from Streptomyces. Anthracyclines are red,
aromatic polyketides and occur in variety of forms due to
the structural differences in the aglycone and the different
sugar residues attached [12]. Multiple pathways are
thought to be involved in the cytotoxicity of this class of
anti-cancer drugs, including accumulation in the nucleus
of neoplastic and proliferating cells, DNA intercalation,
interaction with/inhibition of DNA binding proteins (such
as topoisomerase II-TopII, RNA polymerase, histones), free
radical generation, and antiangiogenic mechanism [13].intenance of cardiovascular tissue homeostasis through the control of
vessel remodelling and angiogenesis. Growth factors as VEGF, or
cules from ECs, including NO, PGI2, AngII and ET, which, in turn,
/or FGF2 production, involved in contractile function and EC survival
re to conventional chemoterapeutic drugs or target therapies,
ng cascades that promote undesired cancer cell proliferation, but also
ction is regarded as a decrease of NO released from ECs, an increase
transmigration of inflammatory cells, which in turn sustain atherosclerosis,
is crucial in heart damage. Different categories of drugs have been
lar diseases associated to treatment with chemotherapeutic agents.
, PKCε agonist and ALDH2 activators. (VEGF: vascular endothelial growth
rostacyclin; AngII: angiotensin II; MAPK: Mitogen activated proteine kinase;
Cs: vascular smooth muscle cells)
Table 1 Effect of chemotherapeutic agents on various metabolic pathways and functions of human ECs
Drug Research type Vascular action
Doxorubicin, daunorubicin In vitro Impairment of NO-dependent function DNA damage, ROS generation, caspases
3 & 7 activation, apoptosis
Cisplatin In vitro Increased expression of ICAM-1, tPA, PAI-1, CRP, ROS
Paclitaxel, docetaxel In vitro Cytoskeleton disruption, impairment of proliferation, migration, prothrombotic effect
5-fluorouracil In vitro Blockade of DNA synthesis; disruption of endothelial layer
Trastuzumab Clinical Impairment of endothelial NO production, ROS generation
VEGF inhibitors Clinical Blockade of VEGF – dependent pro-survival mechanisms in endothelium
Impairment of endothelial NO production, vasoconstriction, haemorrhages
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a complex response, influenced by various mechanisms,
including drug-accumulation in nuclei [14] and mito-
chondria [15], and DNA repair [16], stress-induced
signaling mechanisms [17], sarcoplasmic reticulum
stress [18], nitrosative stress [19], the activity on drug
transporters (including MDR1 and MRP1) [20], drug
metabolism [21], and TopI and II inhibition [15, 22].
TopII is a cellular target for anthracyclines [22]. In
mammals, there are two isoenzymes of TopII: TopIIa
and TopIIb. TopIIa, expressed only in proliferating cells
as tumor cells [23], is thought to be the molecular basis
for the anthracyclines’ anticancer activity. The ubiqui-
tous TopIIb has elevated expression in terminally differ-
entiated cells, including adult endothelial cells [24].
Thus, TopIIb may directly contribute to the develop-
ment of anthracycline-induced endothelial toxicity and
cardiomyopathy [25]. The observation that pixantrone, a
novel anthracycline used in refractory-relapsed non-
Hodgkin lymphoma, ineffective on TopIIb, lacked endo-
thelial toxicity and cardiotoxicity, supports the hypoth-
esis that inhibition of TopIIb plays a key role on
anthracycline toxicity. However, pixantrone differs from
anthracycline for other functional properties potentially
associated with its specific toxicity [26, 27].
A better understanding of these mechanisms will help
design a rational strategy against the endothelial toxicity
of anthracyclines. A liposomal-derived doxorubicin
formulation may be used as an alternative, as it is as-
sociated with reduced cardiovascular toxicity [28].
Liposomal doxorubicin seems also to be endowed
with lower endothelial toxicity, reduced caspase-3 ac-
tivation and preservation of anti-apoptotic protein
Mcl-1 expression in cultured ECs, as compared with
doxorubicin [29].
Almost every chemotherapeutics display significant
detrimental effects on endothelial function [30]. Cisplatin
and most other platinum compounds are simple inorganic
molecules containing a platinum ion. Platinum com-
pounds induce tumor apoptosis by activation of signal
transduction leading to the death receptor mechanisms aswell as mitochondrial pathways. Apoptosis is responsible
for the characteristic nephrotoxicity, ototoxicity and most
other cytotoxicity of these drugs. Cisplatin-induced cyto-
toxicity in endothelial cells has been associated with
increased formation of pro-coagulant endothelial micro-
particles [31] and free radicals [32]. For example, testicular
cancer patients treated with cisplatin showed increased
plasma levels of the endothelial pro-thrombotic markers
PAI-1 and vWF, compared to patients treated only with
orchiectomy [33]. Further, Vaughn et al. [34] found that
NO-dependent vasodilation (flow-mediated vasodilation)
in the brachial artery was impaired in long-term cancer
survivors that had received cisplatin-based chemotherapy
as compared to chemotherapy-naive patients. These
observations suggest that, to protect the EC function, and
consequently preserve cardiovascular health, patients
treated with alkylating agents such as cisplatin would
benefit from association of anti-coagulant or anti-
thrombotic drugs [33, 34]. Indeed, recent evidence sug-
gested enhanced platelet activation in tumors (eg, colon
cancer), and a reduction in the incidence and mortality for
colon cancer in individuals under chronic treatment with
low-doses of aspirin, as that recommended for the preven-
tion of atherothrombosis [35]. Ongoing primary preven-
tion and adjuvant trials (eg, ADD-Aspirin Trial) of low-
dose aspirin will be of help to investigate the contribution
of this strategy on chemotherapy-associated cardiovascu-
lar toxicity.
5-fluorouracil (5-FU), a widely used antimetabolite,
is a pyrimidine analogue which has been reported to
control tumor growth by various mechanisms, in-
cluding inhibition of thymidylate synthase by 5-
fluoro-2′-deoxyuridine-5′-monophosphate, incorporation
of 5-fluorouridine-5′-triphosphate into RNA and incorp-
oration of 5-fluoro-2′-deoxyuridine-5′-triphosphate into
DNA [36]. In ECs, 5-FU was found to suppress the angio-
genic process by blocking the stimulatory effect of vascu-
lar endothelial growth factor (VEGF) on DNA synthesis
during EC mitosis [37] and to induce ROS-induced endo-
thelial damage [38]. Although inhibition of EC prolifera-
tion during tumor angiogenesis is a relevant strategy to
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VEGF inhibition also disturbs endothelial cell homeostasis
and accelerates atherogenesis and arterial thrombembolic
events often resulting in myocardial infarction, cerebro-
vascular insults, and peripheral or mesenteric ischemia
[39–41] (Fig. 1). It may be suggested to accompany treat-
ment with 5-FU or analogous by drugs protecting endo-
thelial cell function, but clinical evidences on the activity
of the latter regarding the anti-tumor efficacy of 5-FU are
actually not available.
Microtubule-binding drugs, e.g. taxanes, are diterpenes
produced by the plants of the genus Taxus. Their main
mechanism of action involves the inhibition of cell div-
ision, chromatid separation and growth, ultimately lead-
ing to cell death. These drugs are commonly known as
mitotic inhibitors or microtubule inhibitors as they
cause a “frozen” mitosis. As with various cancer cells,
taxanes impair basic functions also of ECs, such as pro-
liferation and invasion [42]. Paclitaxel also increases
endothelial tissue factor (TF) expression via its stabiliz-
ing effect on microtubules and activation of c-jun kinase
(JNK), thus leading to downregulation of thrombomodu-
lin and increased protein nitration [43]. Another tubulin
blocker, vincristine, has been shown to adversely affect
rat cardiac microvascular ECs [44]. Endothelial damage
has also been reported for other classical chemotherapeu-
tics, including cyclophosphamide (a nitrogen mustard
inducing DNA alkylation) [45], bleomycin (anti-tumor
antibiotic inducing DNA degradation) and vinca alkaloids
(depolarizing agents causing spiral-like distortions of the
cellular microtubules) [46]. Taken together, these data
suggest that various chemotherapeutics display clinically
relevant endothelial damage (Table 1). Accordingly, evalu-
ation of endothelial toxicity of chemotherapeutics could
potentially lead to the design/identification of preventive
strategies to preserve endothelial function, and, in turn, to
reduce the risk for CVDs in long-term cancer survivors
without affecting drug-associated anti-tumor efficacy.
Target therapies
Endothelial damage is also a common feature of various
novel biological chemotherapeutics, as anti-VEGF agents
(bevacizumab, sunitinib, sorafenib, lapatininb) and anti-
Her2 (trastuzumab) [47, 48]. In clinical trials, 25 % of
patients receiving trastuzumab developed systolic dys-
function especially when administered with or shortly
after doxorubicin [48–51]. Her2 inhibition was also
shown to cause impairment of vascular function through
a reduction in NO bioavailability and an increase in ROS
production [52, 53].
Furthermore, highly effective VEGF inhibitors have
also been associated with endothelial toxicity. Anti-
VEGF treatment consistently predisposes patients to ei-
ther thrombosis or bleeding [39], as well as to systemichypertension, which represents the most common side
effect of anti-VEGF treatment [40, 41]. Beside capillary
rarefaction, mechanisms leading to endothelial dysfunc-
tion and hypertension by VEGF inhibitors are related to
reduced NO production, increased ET-1 release and al-
tered renin-angiotensin system [54, 55].
Another mechanism of hypertension may be related to
the VEGF-mediated suppression of nephrin, which is im-
portant for the maintenance of the glomerular slit dia-
phragm and may contribute to the proteinuria seen with
this class of tyrosine kinase inhibitors [56].
The antiangiogenic multiple kinase inhibitors sunitinib
and sorafenib target a range of different receptor tyro-
sine kinases and other intracellular kinases. Sunitinib
and sorafenib, for example, are known to also inhibit
platelet derived growth factor receptor (PDGFR), which
plays a critical role in angiogenesis and cardioprotection
in the setting of pathologic stress. Recent data have
suggested a novel mechanism for sunitinib-induced car-
diotoxicity, as the drug appears to cause coronary micro-
vascular dysfunction, postulated to be due to loss of
pericytes [57]. PDGFR inhibition impairs the growth and
survival of pericytes, a cell type closely associated with
the microvasculature and supporting the microvascular
function of some tissues [58, 59]. Both sunitinib and
sorafenib are also known to inhibit the stem cell
growth factor receptor known as c-Kit or CD117,
which is expressed by precursors of hematopoietic
stem cells and endothelial progenitor cells, functioning in
the mobilization of these cells to sites of injury [60].
In summary, there is pre-clinical evidence that target
therapies for cancer cells frequently affect EC functions,
resulting in impaired pro-survival and pro-angiogenic
signaling [61]. As reported for conventional chemothera-
peutic drugs, the use of target therapy is a beneficial
strategy to control tumor progression, but requires the
development of new approaches to protect ECs from the
direct and/or indirect cytotoxicity of these compounds
(Fig. 1).
Drugs protecting endothelial cell damage
associated to chemotherapeutic agents
Different classes of drugs have clearly been shown to
improve endothelial function and in some instances to
reduce the risk of CVDs associated to treatment with
chemotherapeutic agents. Among them, angiotensin
converting enzyme inhibitors (ACEi), antioxidants
and statins have direct effects on ECs, while angio-
tensin receptor blockers (ARBs), renin inhibitors,
beta blockers, and estrogens indirectly affect EC function
(Fig. 1) [29, 47, 62–64]. All these drugs have in common
the ability to upregulate the eNOS pathway leading to an
increase in plasma NO availability and a general improve-
ment of endothelial function [4].
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blockers are fundamental therapies in chronic heart fail-
ure (HF), while NO donors and antioxidant strategies
are non-standard HF treatments and represent experi-
mental approaches.
ACEi
In vivo, the protective effects of ACEi on anthracycline
cardiotoxicity are not simply related to hemodynamic ef-
fects due to reduced AngII production, like reductions
in post-load and persistent mitigation of sympathetic
tone [62], but also to direct anti-remodeling, antifibrotic
and antioxidant properties which rate this class of drugs
as a first line HF therapy [65]. In accordance, ACEi pre-
vent decrements of left ventricular ejection fraction
(LVEF) even if they are administered after anthracy-
clines, cardiomyocyte necrosis and increase of circulat-
ing troponin [62]. In long term, inhibition of cardiac
remodeling would be important for ACEi to prevent late
cardiovascular sequelae. Meta-analysis and retrospective
studies on cancer patients treated with anthracyclines,
trastuzumab and tyrosine kinase inhibitors who had
developed a drop in LVEF, showed that cardioprotective
interventions with ACEi, or with beta blockers, statins
and ARBs lead to recovery of myocardial function and
reduction of cardiac events, thus allowing patients to
complete cancer therapy [64, 66]. The temporal indica-
tion is that initiation of ACEi and beta blocker treatment
should be started as soon as possible after completing
chemotherapy [67]. Indeed, no response was observed
in patients in whom therapy was initiated >6 months
after completion of chemotherapy [68]. The use of
ACEi in the prophylaxis of anthracycline-related
cardiac dysfunction has been confirmed recently by
various authors [69, 70], while their efficacy on tras-
tuzumab treated patients has not firmly been demon-
strated, yet [71] and this remains an area of active
investigation (NCT00459771, www.clinicaltrials.gov).
The results of prospective studies have been re-
cently published, demonstrating that ACEi pre-
treatment or co-treatment of patients suffering of
different cancers have a significant preventive effect
on cardiotoxicity induced by anthracyclines [72, 73].
Both components of the heart, the microvascular
endothelium and cardiomyocytes, are target of the
toxic effect of doxorubicin. The number of ECs is 3
fold higher than that of cardiomyocytes, and the vas-
cular component in the heart is crucial for proper
functions of cardiomyocytes [1, 2]. Thus, it is im-
portant to target the coronary microcirculation to
provide benefits to the heart besides the systemic
and cardiac effects.
The vascular protective properties of ACEi seem re-
lated to multiple mechanisms as activation of eNOS(dependent on its turn from bradykinin improved half-
life), stimulation of protective intracellular signaling and
metabolic pathway, and antioxidant and ROS scavenger
properties. Our attention was particularly focused on the
sulphydryl group (−SH) containing lipophilic compound,
zofenoprilat, the active moiety of the prodrug zofenopril,
which, in comparison with other ACEi, is known to
accumulate intracellularly [74, 75]. We previously
demonstrated a central role of fibroblast growth fac-
tor (FGF-2)/FGF receptor-1 system in mediating the
acquisition of an angiogenic phenotype in coronary
microvascular endothelium [76] by zofenoprilat, reported
to exhibit both potent antioxidant and scavenger effects,
and anti-inflammatory action [74]. Zofenoprilat, but not
other ACEi bearing (i.e. captopril) or not (i.e. enalaprilat) a
SH group, was the most potent and effective to promote
endothelial cell survival and ex vivo angiogenesis [77]. In
microvascular endothelium, zofenoprilat up-regulates
eNOS, FGF-2 and telomerase (TERT) mRNA, inducing
cell survival, rescuing damaged ECs and promoting
physiological angiogenesis without synergistic effects with
known angiogenic factors produced by tumors as VEGF
[76, 77]. Recently, we reported the protective properties of
zofenoprilat, known to have an elevated tropism for the
heart, against doxorubicin-induced toxicity in coronary
ECs [78]. The ACEi zofenoprilat preserves coronary EC
survival and function damaged by doxorubicin, and ap-
pears to exert its protective effects owing to its SH group,
besides the ACE inhibitory function [79]. The presence of
a SH group in the zofenoprilat structure suggested us to
investigate the involvement of hydrogen sulfide (H2S) in
the protective effect mediated by zofenoprilat. H2S donors
induce vasodilatation and vessel remodeling [80], protect
ECs from hypoxia/reperfusion damage [81] and exert anti-
inflammatory effects in animal models [82]. Animal
studies documented the protective effect of the ACEi
zofenopril in the reduction of cardiac injury elicited by
doxorubicin [73, 83–85], without affecting its antitumor
efficiency [84]. Moreover, a protective effect by H2S on
doxorubicin induced cardiotoxicity has been recently
reported [86]. We have demonstrated that H2S medi-
ates zofenoprilat activity, since cystathionine γ-lyase
(CSE) is upregulated by the drug and CSE pharmaco-
logical inhibition prevents zofenoprilat protective ef-
fects on doxorubicin induced damage both at a
molecular (p53, caspase-3) and a functional level (cell
survival) [78] (Fig. 2). The evidence that ACEi protects
EC functions potentially suggests that zofenoprilat
might also contribute to normalize vessel phenotype at
tumor level, thus contributing to maximize cytotoxic
drug delivery to tumor cells [87, 88].
Altogether, our data reinforce the indication of
the ACEi zofenopril being endothelium protective in
patients exposed to the cytotoxic drug doxorubicin.
Fig. 2 Molecular mechanisms of doxorubicin induced endothelial damage and reversion by the SH-containing ACEi zofenoprilat. Exposure of
bovine coronary post-capillary venular endothelial cells to doxorubicin (D) impaired cell survival by promoting their apoptosis (evaluated as
cleaved caspase-3: Cl. Caspase 3). ERK1/2 related p53 activation was responsible for doxorubicin induced caspase-3 cleavage. pERK1/2 and p53
were evaluated by western blot in EC treated with 0.5 μM doxorubicin (D) for 1 h, while the cleavage of caspase-3 was monitored by western
blotting in EC exposed to doxorubicin for 6 h. P53 mediated-apoptosis and impairment of survival were reverted by treatment with zofenoprilat
(Z), added at 1–100 μM concentration together with doxorubicin. The previously described prosurvival signaling pathway (activation of PI-3K
dependent eNOS and upregulation of endogenous FGF-2 and telomease reverse transcriptase TERT) [77] was not involved in the protective effect
of doxorubicin induced damage, which, instead, could be ascribed to cystathionine gamma lyase (CSE) dependent availability of H2S from
zofenoprilat. Indeed the levels of CSE protein were upregulated by zofenoprilat treatment (10 μM, 4 h) [78]
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ECs finely control vasomotor responses through the pro-
duction and metabolism of vasoactive molecules acting
on smooth muscle cells, as endothelin-1 (ET-1), nitric
oxide (NO), prostacyclin I2 (PGI2), and angiotensin II
(AngII) (Fig. 1). Moreover, endothelial cells control vas-
cular permeability, especially in microvascular districts,
release molecules that impact on the coagulation and fi-
brinolytic systems, and synthesize several growth factors,
by which ECs interact with circulating cells and support
their survival. The most important growth factor pro-
duced by ECs is FGF-2, which remains cell-associated or
deposited in the extracellular matrix and acts in an auto-
crine/paracrine manner [89].
Concerning the management of VEGF inhibitors-
induced hypertension, there are few case-reports of the
efficacy of long-acting NO donor drugs in two patients
who were treated with antiangiogenic cancer therapies
and were resistant to conventional antihypertensive
drugs [90]. Given the hypothesized role of decreased NO
signaling in the pathogenesis of hypertension with these
agents, NO donor drugs with peculiar and controlled
NO release kinetics and able to preserve/restore endo-
thelial survival and function may be a mechanisticallyrelevant class of drugs to use (Fig. 1). However the effi-
cacy of NO donors or drugs able to upregulate eNOS in
contributing to vessel normalization without counteract-
ing the antineoplastic/antiangiogenic effect of drugs
impairing the aberrant VEGF signaling at tumor level re-
mains to be validated both at the experimental and the
clinical level.
In this context, we have contributed to demonstrate
that microvascular endothelium, in particular from the
coronary post-capillary microcirculation, is able to main-
tain a prosurvival phenotype through the upregulation
of eNOS which fine-tunes the release of nanomolar
amounts of NO, resulting in activation of cGMP and
MAPK pathways, finally controlling the transcription of
FGF-2 mRNA at the nuclear level [89, 91–95] (Fig. 3).
Indeed, stress insults as serum deprivation and ROS-
induced cytotoxic mediators impair the eNOS/FGF-2
pathway [96–98]. Therapeutic strategies able to restore
eNOS functioning and FGF-2 production and release
have been developed and investigated, as activators of
PKCepsilon isoform [99], novel NO donor drugs based
on metallic centers [100], a VEGF mimetic peptide
named QK [101] and the mitochondrial aldehyde
dehydrogenase (ALDH2) activator, called Alda-1 [102]
Fig. 3 Metabolic pathways preserving EC function. ECs maintain a prosurvival phenotype through the upregulation of eNOS, the activation of
cGMP, Akt and MAPK pathways, and the transcription of FGF-2. ACEi, PKCε activators, novel NO donor drugs, VEGF mimetic peptides and ALDH2
activator have been reported to modulate eNOS activity and/or FGF-2 expression, suggesting a potential application of these drugs in association
with chemotherapeutic drugs to preserve EC function and to reduce the risk for CVDs in long-term cancer survivors
Fig. 4 Molecular mechanisms of zofenoprilat-induced protective
effects on vascular ECs. Zofenoprilat induces a constant H2S
production through CSE upregulation in vascular endothelium.
On its turn H2S maintains ECs survival and stimulates the angiogenic
process through a sequential pathway involving KATP channel/Akt/
eNOS/ERK1/2 pathway (for details see [104])
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been also reported to alleviate doxorubicin toxicity [103].
As reported above, the ACEi zofenoprilat exerts
endothelium protective properties through off-target
mechanisms in endothelial cells, as CSE activation
and, in turn, increase H2S availability. We have re-
cently reported that ACEi dependent H2S exerts pro-
tective activity on ECs through activation of KATP
channel, PI-3 K and eNOS, as well as up-regulation
of FGF-2 and telomerase, thus maintaining endothe-
lial longevity and function [76–78, 104] (Fig. 4).
In conclusion, these preventive strategies, reported to
preserve endothelial cell function, may be useful in asso-
ciation with chemotherapeutic agents to reduce the risk
for CVDs in long-term cancer survivors.
Antioxidants
Clinical use of antioxidants to protect the heart during
anthracycline chemotherapy has been controversial due
to the potentially reduced cytotoxic efficacy toward can-
cer cells. Results from randomized clinical trials address-
ing the issue whether antioxidants either reduce the
incidence of clinical heart failure among patients under-
going anthracycline-based chemotherapy or reduce the
response rates to anthracycline-based chemotherapy,
have been unclear and need to be revised [105]. Studies
in vitro and in animal models have explored the role of
incorporating antioxidants with anthracyclines in the
hope of reducing oxidative damage to cardiac cells. Early
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dants found in the diet, which are known to prevent
cellular oxidative damage. Many animal models showed
a reduction in anthracycline cardiotoxicity by co-
administering compounds such as vitamin E, vitamin C,
vitamin A, coenzyme Q, and flavonoids. Other pharma-
ceutical compounds with known antioxidant properties,
such as probucol, carvedilol, N-acetylcysteine and dan-
trolene, have also been found to protect cardiac damage
in animal models (see [105] for details).
Consistent with the “iron and free radical hypothesis”,
the mechanism of action of the only clinically approved
drug to prevent anthracycline-mediated cardiotoxicity,
dexrazoxane (ICRF-187), was based on its iron-chelating
effects [106]. However, accumulated evidence suggests
that ROS-dependent mechanisms cannot fully account
for anthracycline toxicity. For example, doxorubicin-
induced DNA strand breakage was found to be inde-
pendent of the induction of oxidative DNA damage,
while lovastatin reduced doxorubicin-triggered strand
breaks without affecting ROS formation [107]. Further-
more, dexrazoxane appeared to be a catalytic inhibitor of
TopII, suggesting that protection against anthracycline-
induced toxicity could be exerted also via the TopII
inhibition, not only via the iron chelation activity of
the drug [108].
Other medications that have antioxidant properties
may also be effective therapies for chemotherapy-induced
cardiovascular damage. HMG-CoA reductase inhibitors,
or statins, have been shown to have pleiotropic effects in-
cluding antioxidant and anti-inflammatory properties, but
clinical data are necessary to confirm their efficacy in pre-
venting cancer therapy-related endothelial and cardio-
toxicity [64, 107, 109, 110]. Indeed, antioxidant strategies
are not established therapies in this setting [70].
In conclusion, if antioxidants are confirmed to reduce
anthracycline-associated toxicity while maintaining the
drug-associated-antitumor effect, they would provide a
useful tool to prevent cardiovascular damage.
Drugs affecting endothelial cell metabolism
Healthy ECs generate energy through glycolysis
[102, 111, 112], and mitochondria represent essen-
tially a bioenergetic reserve on which they count
under stress conditions [113]. Recently, we demon-
strated the protective role of mitochondrial aldehyde
dehydrogenase-2 (ALDH2) in ECs exposed to stress
insult [102]. ALDHs are a family of NADP-dependent en-
zymes with common structural and functional features that
catalyze the oxidation of a broad spectrum of aldehydes.
Three major classes of mammalian ALDHs have been iden-
tified, named 1, 2 and 3. Classes 1 and 3 contain both con-
stitutive and inducible cytosolic isozymes [114]. Class 2
consists of constitutive mitochondrial isozymes [114].The ALDH dysfunction has been associated with myo-
cardial infarction and hypertension [115], as well as with
doxorubicin-mediated cardiotoxicity [103]. For example,
ALDH2 has been reported to play a central role in the
vasodilator actions of nitroglycerin, and in protecting is-
chemic myocardium. By preventing ALDH2 inactivation
by stress insult, the ALDH2 selective agonists reduce the
extent of infarction-induced injury [103, 115].
Further, experimental data have demonstrated that
endothelial progenitor cells expressing high levels of
ALDH, isolated from bone marrow or peripheral blood,
are critical for vascular recovery of the ischemic regions
[111]. Within the pancreas, ALDH expressing cells pro-
mote islet revascularization after transplantation into
streptozotocin-treated mice [112], suggesting that high
expression of ALDH in proangiogenic cells plays a key
role in tissue vascularization.
In this context, we showed that in ECs exposed to a
cytotoxic insult, by preventing the inactivation of the
constitutive mitochondrial ALDH2, we could restore
mitochondrial functions and rescue the pro-angiogenic
functions [102]. We observed that ALDH2 activation
promotes growth of cultured endothelium and its ability
to form cord-like structures in vitro, similar to those ob-
served in vivo during tissue revascularization. Specific-
ally, our findings demonstrate that activation of ALDH2
prevents the injurious effects of aldehydes on vascular
endothelium, preserving EC-associated responsiveness.
These results suggest that the above described molecules
may be potentially useful to preserve ECs from damage-
associated with the treatment with chemotherapeutic
drugs.
However, since high ALDH metabolic activities have
been observed not only in ECs but also in tumor cells,
and ALDH expression in tumor cells has been reported
to confer resistance to chemotherapeutic agents as
cyclophosphamide [116], inhibitors of ALDH have been
proposed in cancer treatment. As observed for anthracy-
clines, ALDH inhibition in ECs may damage crucial
metabolic signaling cascades that protect ECs and cardi-
omyocytes, especially in response to stress [103]. In this
context, it is essential to understand whether ALDH
isozymes in ECs might govern their metabolic activity
during angiogenesis, and whether they might be a new
anti-metabolic/anti-angiogenic druggable target.
Concluding remarks
It has become clear that cancer patients should be man-
aged by a team of oncologists and cardiologists, as sys-
temic effects of chemotherapeutic drugs, among which
cardiovascular are the most important, may occur more
frequently [117].
Drugs shown to directly improve endothelial function
and to reduce the risk of CVDs associated to treatment
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and statins, while angiotensin receptor blockers, renin
inhibitor, beta blockers, and estrogens generally improve
cardiovascular function. Recently, beta blockers have
been demonstrated to be important as ACEi in HF from
antineoplastic drugs [68]. The use of drugs that control
platelet aggregation and coagulation is also recommended.
There is the need for evaluating cardiotoxicity of po-
tential novel chemotherapeutic agents through specific
screening modalities [118] and endothelial cytotoxicity
in vitro and in animal models [119], before any drug is
approved in clinical trials. The above data show that
drug-induced cardiac toxicity can have a multicellular
component, in particular most of chemotherapeutic
drugs target ECs. This has profound implications for the
development of in vitro preclinical cardiovascular tox-
icity screens within the pharmaceutical industry, based
on detecting adverse effects in cardiomyocytes. There is
a need for multicellular models (e.g. co-cultures) that re-
constitute cardiac physiology to allow researchers to
simultaneously investigate structural and functional
changes in different cardiac cell types. As an example,
the use of Zebrafish comes in help to study the forma-
tion of the vertebrate vascular network. The small size
and optical translucency of the zebrafish embryo, in
combination with huge amounts of fluorescent trans-
genic lines which allow direct visualization of in vivo
vessel formation during embryogenesis, have greatly ad-
vanced our understanding of vascular biology and
should help us to investigate the cardiovascular toxicity
of chemotherapeutic drugs [120].
There is the medical need to identify patients at
risk of developing cardiotoxicity as early as possible
before and during chemotherapy by the definition of
validated biomarkers of vascular and cardiac toxicity
[70, 117, 121, 122]. Novel potential robust approaches
to address this issue include measurement of circulat-
ing miRNAs [123] and the use of metabolomics to
identify metabolic signatures in the circulation which
are indicative of endothelium injury. These may help
to detect changes of cardiotoxicity [124].
Endothelial metabolism and signalling pathways
such as eNOS, FGF-2 or ALDH activity may be novel
targets for drugs with a protective effect against the
cardiovascular toxic effects of chemotherapeutic agents.
Further, identification of metabolic determinants govern-
ing the metabolic shift of endothelial cells during tumor
angiogenesis, might also allow to identify new anti-
metabolic/anti-angiogenic targets to be exploited in can-
cer treatment.
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